N-[1-({7-[(4-hydroxypiperidin-1-yl)methyl]-2-naphthyl}methyl)piperidin-4-yl]-3-methoxybenzamide | 1018071-38-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[1-({7-[(4-hydroxypiperidin-1-yl)methyl]-2-naphthyl}methyl)piperidin-4-yl]-3-methoxybenzamide
• 英文别名: N-[1-[[7-[(4-hydroxypiperidin-1-yl)methyl]naphthalen-2-yl]methyl]piperidin-4-yl]-3-methoxybenzamide
• CAS: 1018071-38-9
• 化学式: C₃₀H₃₇N₃O₃
• 分子量: 487.642
• InChiKey: NOWCQTCAIUPAFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  65
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP2098509A1

  公开（公告）日：2009-09-09

  Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

  本发明公开了一种药物组合物，其中包含由式 (I) 代表的化合物 或其药学上可接受的盐作为活性成分，对黑色素浓缩激素受体具有拮抗活性。由于其对 MCH 受体的拮抗活性，该药物组合物可用于预防或治疗抑郁症、焦虑症（如：广泛性焦虑症、创伤后焦虑症）等疾病、广泛性焦虑症、创伤后应激障碍、恐慌症、强迫症、社交焦虑症）、注意力缺陷障碍、躁狂症、躁狂抑郁症、精神分裂症、情绪障碍、压力、睡眠障碍、发作、记忆障碍、认知障碍、痴呆、健忘、谵妄、肥胖、进食障碍、食欲障碍、多食症、贪食症、嗜食症、糖尿病、心血管疾病、高血压、血脂异常、心肌梗塞、运动障碍（如嗜睡症g.,帕金森病、癫痫、抽搐、震颤）、药物滥用和药物成瘾。